The in vivo metabolism of 3-oxo-5-benzylidene-6-methyl-(4H)-2-(benzoylmethyl)pyridazine in rats.
The purpose of the study was to investigate the in vivo metabolic pathway of 3-oxo-5-benzylidene-6-methyl-(4H)-2-(benzoylmethyl)pyridazine (substrate) in rats. Firstly its potential metabolites, i.e. N-dealkylation, ring scission of pyridazine and aromatic hydroxylation products, were synthesized and then the substrate was given orally (100 mg/kg) to male or female Wistar rats at a dose of 100 mg/kg to body weight. Blood samples were collected at 0, 1, 2, 4, 6 and 8 hours after administration of substrate and blood was centrifuged to obtain serum. The substrate and its potential metabolites were separated using a gradient HPLC method on a reverse phase system. This study revealed that 3-oxo-5-benzylidene-6-methyl-(4H)-2-(benzoylmethyl)pyridazine was not metabolized to the proposed metabolites and was present unchanged in the serum.
Oruç
E Elçin
EE
Marmara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Istanbul, Turkey.
Unsal
Oya
O
Balkan
Ayla
A
Ozkanli
Fügen
F
Gören
M Zafer
MZ
Terzioğlu
Berna
B
Rollas
Sevim
S
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000138:chemical synthesis / Q000378:metabolism*; D001711:Biotransformation; D002406:Catheterization, Peripheral; D002851:Chromatography, High Pressure Liquid; D003640:Dealkylation; D005260:Female; D006900:Hydroxylation; D007083:Iliac Artery; D008297:Male; D011724:Pyridazines / Q000097:blood / Q000138:chemical synthesis / Q000378:metabolism*; D051381:Rats; D012015:Reference Standards; D012996:Solutions
C511936:3-oxo-5-benzylidene-6-methyl-(4H)-2-(benzoylmethyl)pyridazine; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011724:Pyridazines; D012996:Solutions